SK Capital to Invest in Swixx BioPharma in Deal Valued at Over €1.5 Billion
December 15, 2025
SK Capital Partners, through an affiliate, reached a definitive agreement to invest in Swixx BioPharma AG as the company looks to accelerate its next phase of growth and global expansion. The transaction values Swixx at more than €1.5 billion, with Swixx co-founders and CEO/CFO retaining significant ownership and existing investors HBM Healthcare Investments and Mérieux Equity Partners remaining shareholders.
- Buyers
- SK Capital Partners
- Targets
- Swixx BioPharma AG
- Industry
- Healthcare Services
- Location
- Switzerland
- Transaction Type
- Growth capital
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.